am 251 has been researched along with Chronic Disease in 4 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Stress contributes to major depressive disorder (MDD) and chronic pain, which affect a significant portion of the global population, but researchers have not clearly determined how these conditions are initiated or amplified by stress." | 1.62 | mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress. ( Han, J; Huang, M; Luo, L; Ma, X; Shi, H; Su, C; Wang, A; Wang, H; Wang, W; Wu, K; Xu, T; Xu, X; Yuan, T, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malvestio, RB | 1 |
| Medeiros, P | 1 |
| Negrini-Ferrari, SE | 1 |
| Oliveira-Silva, M | 1 |
| Medeiros, AC | 1 |
| Padovan, CM | 1 |
| Luongo, L | 1 |
| Maione, S | 1 |
| Coimbra, NC | 1 |
| de Freitas, RL | 1 |
| Xu, X | 1 |
| Wu, K | 1 |
| Ma, X | 1 |
| Wang, W | 1 |
| Wang, H | 1 |
| Huang, M | 1 |
| Luo, L | 1 |
| Su, C | 1 |
| Yuan, T | 1 |
| Shi, H | 1 |
| Han, J | 1 |
| Wang, A | 1 |
| Xu, T | 1 |
| Reich, CG | 1 |
| Mihalik, GR | 1 |
| Iskander, AN | 1 |
| Seckler, JC | 1 |
| Weiss, MS | 1 |
| Rossi, S | 1 |
| De Chiara, V | 1 |
| Musella, A | 1 |
| Kusayanagi, H | 1 |
| Mataluni, G | 1 |
| Bernardi, G | 1 |
| Usiello, A | 1 |
| Centonze, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Study of Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors[NCT03530800] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The entire study lasts 10 weeks. Every two weeks subjects will take the NIMH-TSS. The change in scores from baseline to after 10 weeks will be assessed. The scale itself assesses severity of trichotillomania symptoms. The NIMH-TSS score ranges from 0 to 20, with 0 being no symptoms and 20 being the most severe. (NCT03530800)
Timeframe: Assessed every two weeks up to 10 weeks, baseline data reported
| Intervention | score on a scale (Mean) |
|---|---|
| Dronabinol | 12.38 |
| Placebo | 10.63 |
The entire study lasts 10 weeks. Every two weeks subjects will take the SP-SAS. The change in scores from baseline to after 10 weeks will be assessed. The scale itself assesses severity of skin-picking symptoms. The SP-SAS score ranges from 0 to 48, with 0 being no symptoms and 48 being the most severe. (NCT03530800)
Timeframe: Assessed every two weeks up to 10 weeks, baseline reported
| Intervention | score on a scale (Mean) |
|---|---|
| Dronabinol | 24.44 |
| Placebo | 28.5 |
4 other studies available for am 251 and Chronic Disease
| Article | Year |
|---|---|
Cannabidiol in the prelimbic cortex modulates the comorbid condition between the chronic neuropathic pain and depression-like behaviour in rats: The role of medial prefrontal cortex 5-HT
Topics: Animals; Cannabidiol; Chronic Disease; Cobalt; Depression; Limbic System; Microinjections; Neuralgia | 2021 |
mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress.
Topics: Animals; Cannabinoid Receptor Antagonists; Chronic Disease; Depressive Disorder, Major; Endocannabin | 2021 |
Adolescent chronic mild stress alters hippocampal CB1 receptor-mediated excitatory neurotransmission and plasticity.
Topics: Animals; Benzoxazines; Chronic Disease; Disease Models, Animal; Excitatory Postsynaptic Potentials; | 2013 |
Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum.
Topics: Animals; Chronic Disease; Corpus Striatum; Dronabinol; Excitatory Amino Acid Antagonists; Excitatory | 2008 |